Denali Therapeutics (DNLI) disclosed Friday morning that it was informed by its strategic partner Sanofi (SNY) that the Phase 2 HIMALAYA study evaluating SAR443820/DNL788 in participants with amyotrophic lateral sclerosis did not meet the primary endpoint of change in ALS Functional Rating Scale-Revised. SAR443820/DNL788 is an investigational oral brain-penetrant RIPK1 inhibitor being co-developed by Sanofi and Denali. Sanofi will continue to conduct the K2 Phase 2 study of SAR443820/DNL788 in participants with multiple sclerosis, Denali adds. Shares of Denali are down 2% to $16.65 in premarket trading.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DNLI:
- Denali Therapeutics price target lowered to $27 from $32 at Citi
- Denali Therapeutics’ ALS Drug Fails Phase 2, Yet MS Trial Continues
- Denali announces data, expansion of BBB-crossing enzyme replacement therapy
- Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™
- Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™
